Upstream Bio, Inc. (UPB)
NASDAQ: UPB · Real-Time Price · USD
18.01
-4.73 (-20.80%)
Nov 20, 2024, 4:00 PM EST - Market closed
Company Description
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders.
It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor.
The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.
Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.
Upstream Bio, Inc.
| Country | United States |
| Founded | 2021 |
| IPO Date | Oct 11, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 38 |
| CEO | E. Sutherland |
Contact Details
Address: 890 Winter Street, Suite 200 Waltham, Massachusetts 02451 United States | |
| Phone | 781 208 2466 |
| Website | upstreambio.com |
Stock Details
| Ticker Symbol | UPB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0002022626 |
| ISIN Number | US91678A1079 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| E. Rand Sutherland, M.D., M.P.H. | Chief Executive Officer and Director |
| Michael Paul Gray, M.B.A. | Chief Financial and Operating Officer |
| Aaron Deykin, M.D. | Chief Medical Officer and Head of Research and Development |
| Adam Houghton, Ph.D., M.B.A. | Chief Business Officer |
| Ronald C. Renaud, Jr., M.B.A. | Chairman of the Board |
| Erez Chimovits, M.B.A., M.Sc. | Director |
| H. Edward Fleming, Jr., M.D. | Director |
| Dayton Misfeldt+ | Director |
| Liam Ratcliffe, M.B.Ch.B., Ph.D., M.B.A. | Director |
| Marcella Kuhlman Ruddy, M.D., M.S. | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 7, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 7, 2024 | 10-Q | Quarterly Report |
| Nov 7, 2024 | 8-K | Current Report |
| Oct 22, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Oct 18, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 17, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Oct 15, 2024 | 8-K | Current Report |
| Oct 11, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Oct 11, 2024 | 424B4 | Prospectus |
| Oct 10, 2024 | EFFECT | Notice of Effectiveness |